192214-05-4

Basic information

• Product Name: (R)-1-CBZ-3-HYDROXYMETHYLPYRROLIDINE
• Synonyms: (R)-1-CBZ-3-HYDROXYMETHYLPYRROLIDINE;(R)-1-CBZ-BETA-PROLINOL;R-1-Cbz-3-(Hydroxymethyl)piperidine;(R)-benzyl 3-(hydroxyMethyl)pyrrolidine-1-carboxylate;(R)-1-Cbz-3-(hydroxyMethy...;(3R)-3-(Hydroxymethyl)-1-pyrrolidinecarboxylic acid phenylmethyl ester;(R)-3-(Hydroxymethyl)-1-pyrrolidinecarboxylic acid phenylmethyl ester;benzyl (3r)-3-(hydroxymethyl)pyrrolidine-1-carboxylate
• CAS NO: 192214-05-4
• Molecular Formula: C₁₃H₁₇NO₃
• Molecular Weight: 235.28
• Product Categories: pharmacetical
• Mol File: 192214-05-4.mol

Chemical Properties

• Boiling Point: 381.969 °C at 760 mmHg
• Flash Point: 184.809 °C
• Appearance: /
• Density: 1.196 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.561
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (R)-1-CBZ-3-HYDROXYMETHYLPYRROLIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-1-CBZ-3-HYDROXYMETHYLPYRROLIDINE(192214-05-4)
• EPA Substance Registry System: (R)-1-CBZ-3-HYDROXYMETHYLPYRROLIDINE(192214-05-4)

Safety Data

• Hazardous Substances Data: 192214-05-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(R)-1-CBZ-3-HYDROXYMETHYLPYRROLIDINE is used as a chiral intermediate for the synthesis of pharmaceuticals, particularly in the production of drugs. Its unique structure and properties make it valuable in the development of new drugs and the creation of various pharmaceutical products.
Used in Medicinal Chemistry:
(R)-1-CBZ-3-HYDROXYMETHYLPYRROLIDINE is used as a key component in the field of medicinal chemistry, where it aids in the design and synthesis of novel drug candidates. Its chiral nature and functional groups enable the development of enantiomerically pure compounds, which are essential for the therapeutic efficacy and safety of pharmaceuticals.
Used in Drug Discovery:
(R)-1-CBZ-3-HYDROXYMETHYLPYRROLIDINE is employed in drug discovery processes to identify and optimize potential drug candidates. Its unique structure and properties allow researchers to explore new chemical space and develop innovative therapeutic agents with improved pharmacological profiles.

InChI:InChI=1/C13H17NO3/c15-9-12-6-7-14(8-12)13(16)17-10-11-4-2-1-3-5-11/h1-5,12,15H,6-10H2/t12-/m1/s1

Upstream product

• 99735-47-4 (3R)-1-[(R)-1-phenylethyl]-3-(hydroxymethyl)pyrrolidine 
• 501-53-1 benzyl chloroformate 
• 192214-04-3 (R)-1-Benzyl-3-benzyloxymethyl-pyrrolidine 
• 192214-02-1 β-azidomethyl γ-butyrolactone 
• 172796-28-0 (R)-4-((benzyloxy)methyl)dihydrofuran-2(3H)-one 
• 85701-08-2 (R)-4-(hydroxymethyl)dihydrofuran-2(3H)-one 
• 5082-74-6 (R)-(+)-3-(hydroxymethyl)pyrrolidine 
• 192214-03-2 (R)-1-Benzyl-4-benzyloxymethyl-pyrrolidin-2-one 

Downstream Products

• 1217655-90-7 (R)-methyl-1-benzyloxycarbonyl-pyrrolidine-3-carboxylate 
• 441717-40-4 (R)-methyl-1-tert-butoxycarbonyl-pyrrolidine-3-carboxylate 
• 1436862-03-1 trans-3-[N'-(6-benzyloxy-7-oxo-1,6-diaza-bicyclo[3.2.1]octane-2-carbonyl)-hydrazinocarbonyl]-(R)-pyrrolidin-1-carboxylic acid tert-butyl ester 
• 1212062-74-2 benzyl (3R)-3-formylpyrrolidine-1-carboxylate 
• 405090-09-7 benzyl (R)-3-(((methylsulfonyl)oxy)methyl)pyrrolidine-1-carboxylate 
• 648418-12-6 (R)-3-(4-Benzyloxycarbonylamino-2-fluoro-phenoxymethyl)-pyrrolidine-1-carboxylic acid benzyl ester 
• 790703-05-8 N-{(S)-3-[3-Fluoro-4-((R)-1-pyrrolidin-3-ylmethoxy)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide 
• 192214-06-5 (R)-1-((benzyloxy)-carbonyl)pyrrolidine-3-carboxylic acid 

Relevant articles and documents

AZOLE-SUBSTITUTED PYRIDINE COMPOUND

The present invention provides a compound represented by formula [I'| shown below or a pharmaceutically acceptable salt thereof that has an inhibitory effect on 20-HETE producing enzyme, wherein the structure represented by formula [III] shown below represents any of the structures represented by formula group [IV] shown below, wherein R1 represents a hydrogen atom, a fluorine atom, methyl, etc.; R2, R3, and R4 each independently represent a hydrogen atom, a fluorine atom, or methyl; W represents a single bond, C1-3alkanediyl, or the formula -O-CH2CH2-; and ring A represents (a) substituted C4-6cycloalkyl, (b) substituted 4- to 6-membered saturated nitrogen-containing heterocyclyl, (c) substituted phenyl, (d) substituted pyridyl, (e) substituted 2,3-dihydrobenzofuran, (f) 4- to 6-membered saturated oxygen-containing heterocyclyl, etc.

A urea-biphenyl compound and its composition and use thereof

The invention relates to biphenyl derivatives as well as a preparation method and a pharmaceutical composition and application thereof on medicines. And particularly, the invention relates to novel urea-substituted biphenyl derivatives as well as a pharma

A PROCESS FOR PREPARATION OF (2S, 5R)-7-OXO-6-SULPHOOXY-2-[((3R)-PYRROLIDINE-3-CARBONYL)-HYDRAZINO CARBONYL]-1,6-DIAZA-BICYCLO[3.2.1]OCTANE

A process for preparation of (2S, 5R)-7-oxo-6-sulphooxy-2- [((3R)-pyrrolidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza- bicyclo[3.2.1]octane is disclosed comprising reacting a compound of Formula (II) with a compound of Formula (III) to obtain a compound

Method of treating addiction or dependence using a ligand for a monoamine receptor or transporter

One aspect of the present invention relates to a method of treating of drug addiction or drug dependence in a mammal, comprising the step of administering to a mammal in need thereof a therapuetically effective amount of a heterocyclic compound, e.g., a 3-substituted piperidine. In a preferred embodiment, the method of the present invention treats cocaine addiction or methamphetamine addiction.

Ligands for monoamine receptors and transporters, and methods of use thereof

One aspect of the present invention relates to heterocyclic compounds. A second aspect of the present invention relates to the use of the heterocyclic compounds as ligands for various mammalian cellular receptors, including dopamine, serotonin, or norepinephrine transporters. The compounds of the present invention will find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to addiction, anxiety, depression, sexual dysfunction, hypertension, migraine, Alzheimer's disease, obesity, emesis, psychosis, schizophrenia, Parkinson's disease, inflammatory pain, neuropathic pain, Lesche-Nyhane disease, Wilson's disease, and Tourette's syndrome. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the heterocyclic compounds, and the screening of those libraries for biological activity, e.g., in assays based on dopamine transporters.